This is a welcome text with instructions

Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date
on information about hepatitis and to answer some of our web site and training audience questions.
People are encouraged to submit questions and post comments.

Be sure to check out our other blog: Hepatitis & Tattoos

Alan Franciscus
Editor-inChief
HCV Advocate
HBV Advocate


Tuesday, October 11, 2011

INCIVO® (telaprevir), a new treatment for genotype-1 chronic hepatitis C launched today

High Wycombe, UK, 10th October 2011: INCIVO® (telaprevir)*, a new direct acting antiviral (DAA) protease inhibitor (PI), for the treatment of genotype-1 chronic hepatitis C (hep C), in combination with peginterferon alfa and ribavirin (i.e. current standard treatment), in adults has been launched today in the UK.

Telaprevir, one of a new class of medicines which directly targets the hep C virus, now offers more patients infected with genotype 1 chronic hep C the chance of clearing the virus (achieving sustained virologic response, SVR) compared to current standard treatment.

Read more:
Posted by HCV Advocate at 11:37 AM
Labels: , ,

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)